EMERGING INFECTIOUS DISEASES - OVERVIEW.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. SARS-CoV-2 detection enabled by a portable and label-free photoelectrochemical genosensor using graphitic carbon nitride and gold nanoparticles.Electrochimica acta · 2023
   Article
2. Repellent efficacy of 20 essential oils on Aedes aegypti mosquitoes and Ixodes scapularis ticks in contact-repellency assays.Scientific reports · 2023
   Article
3. Emerging and Re-Emerging Diseases.Pathogens (Basel, Switzerland) · 2021
   Article
4. Quantitative analysis of Anaplasma marginale acquisition and transmission by Dermacentor andersoni fed in vitro.Scientific reports · 2020
   Article
5. Developing an In-House Biological Safety Cabinet Certification Program at the University of North Dakota.Applied biosafety : journal of the American Biological Safety Association · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as